Novartis AG (NYSE:NVS), a leading global healthcare company, is renowned for its innovative pharmaceuticals. The company is a key player in the pharmaceutical industry, competing with giants like Pfizer and Merck.

On October 28, 2025, Novartis reported an earnings per share (EPS) of $2.25, slightly below the expected $2.26. However, the company achieved a revenue of approximately $13.9 billion, surpassing the estimated $13.8 billion, as reported by the Wall Street Journal. This revenue growth is attributed to strong sales of key drugs.

Novartis's third-quarter net profit saw a significant increase to $3.93 billion, driven by higher sales of its key drugs, helping to offset the financial impact of patent expirations. The company's price-to-earnings (P/E) ratio stands at approximately 26.16, reflecting the market's valuation of its earnings.

The price-to-sales ratio of about 4.59 and the enterprise value to sales ratio of around 5.07 highlight the company's strong market position. Additionally, Novartis's enterprise value to operating cash flow ratio of approximately 13.32 indicates its cash flow efficiency. The earnings yield of about 3.82% provides insight into the return on investment, while a debt-to-equity ratio of approximately 0.78 shows a balanced approach to financing. The current ratio of around 0.82 suggests the company's capability to cover short-term liabilities with short-term assets.